Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
64 studies found for:    Behcet's Disease
Show Display Options
Rank Status Study
21 Completed The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease
Condition: Behçet's Disease
Intervention: Other: serum levels of angiogenin, bFGF, VEGF
22 Completed
Has Results
Phase III Study in Refractory Behcet's Disease
Condition: Behcet Disease
Interventions: Drug: AIN457;   Drug: Placebo
23 Recruiting Immunogenetic Mechanisms in Behcet's Disease
Conditions: Behcet's Disease;   Uveitis
Intervention:
24 Completed
Has Results
Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease
Conditions: Behcet Syndrome;   Behcet Disease;   Mucocutaneous Ulceration
Intervention: Biological: Veldona,
25 Completed HAT in Eye Complications of Behcet's Disease
Conditions: Behcet's Syndrome;   Retinal Disease;   Uveitis
Intervention: Drug: Daclizumab
26 Withdrawn A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
Conditions: Muckle Wells Syndrome;   Autoinflammatory;   Behcet's Disease
Intervention: Drug: XOMA 052
27 Unknown  Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB)
Conditions: Behcet's Disease;   Panuveitis;   Posterior Uveitis;   Retinal Vasculitis
Interventions: Drug: Cyclosporin A;   Drug: Interferon-alpha2a
28 Terminated
Has Results
Tocilizumab for the Treatment of Behcet's Syndrome
Condition: Behcet's Syndrome.
Intervention: Drug: Tocilizumab
29 Terminated Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)
Condition: Behcet's Uveitis
Interventions: Drug: Gevokizumab;   Drug: Placebo
30 Recruiting A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome
Condition: Female Patients With Behcet's Syndrome
Intervention: Drug: Abatacept
31 Completed Anakinra for Behcet s Disease
Conditions: Autoimmune/Connective Tissue Diseases;   Immune System Diseases
Intervention: Drug: Anakinra
32 Recruiting Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)
Conditions: Urticaria;   Arthropathy;   Lymphadenopathy;   Nervous System Anomalies
Intervention:
33 Enrolling by invitation VCRC Patient Contact Registry Patient-Reported Data Validation Study
Conditions: Behcet's Disease;   Churg-Strauss Syndrome;   Giant Cell Arteritis;   Wegener Granulomatosis;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
34 Terminated Hematopoietic Stem Cell Support in Vasculitis
Condition: Vasculitis
Interventions: Biological: Autologous Stem Cell Transplant;   Biological: Allogeneic Stem Cell Transplant
35 Completed Efficacy of Humira in Behcet Patients With Arthritis
Condition: Arthritis; Behcet
Intervention: Drug: Adalimumab (Humira)
36 Completed Uveitis Gene-Expression Profiling
Condition: Uveitis
Intervention:
37 Completed Educational Needs of Patients With Systemic Vasculitis
Conditions: Behcet's Disease;   Churg-Strauss Syndrome;   Vasculitis, Central Nervous System;   Giant Cell Arteritis;   Wegener Granulomatosis;   Henoch-Schoenlein Purpura;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
38 Completed Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis
Conditions: Psoriasis;;   Psoriatic Arthritis;;   Psoriasis Arthropatica
Interventions: Drug: Apremilast;   Drug: Placebo
39 Completed
Has Results
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
Conditions: Psoriasis;   Psoriatic Arthritis
Interventions: Drug: Apremilast tablet 30 mg;   Drug: Etanercept 50 mg;   Drug: Placebo tablet;   Drug: Placebo injection (saline)
40 Terminated Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels
Conditions: Coronary Artery Disease;   Inflammatory Response;   Atherosclerosis
Intervention: Dietary Supplement: eicosapentaenoic acid (EPA),

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.